Endothelial cell–released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome Soluble CD93 contributes to podocyte injury, and CD93 blockade emerges as a candidate therapeutic target in INS.

Great paper from @carafuentes-neph.bsky.social !!
Tackling #nephroticsyndrome from many angles, better treatments are on the horizon!
Congrats Gabriel & team!!!!
#FSGS #pediatricnephrology #NephSky #SkyNeph #humangenetics
@science.org
www.science.org/doi/10.1126/...

Great paper !!!
#APOL1 #FSGS

In this interview, Dr. Howard Trachtman discusses targeted therapies for FSGS, including BI 764198, a TRPC6 inhibitor that was the subject of a recent study published by The Lancet. #kidneydisease #FSGS #nephrology #nephsky buff.ly/CvQ7u8J

ACTN4 p.Ile150Met Causes #FSGS With Validation in #Primary #Fibroblasts and Immortalized Podocytes

https://doi.org/10.1016/j.ekir.2025.11.030

#KIRResearchLetter

💥 Die Dissertation von FSGS-Alumna Jana Maria Weiß ist bei de Gruyter Brill erschienen.

🔗 Mehr Informationen auf unserer Website. Link im Profil!

#publikation #neuerscheinung #fsgs #paulcelan

❄️ Nach einem produktiven und erfolgreichen Wintersemester verabschieden wir uns nun in die Semesterpause. Wir wünschen euch gute Erholung und freuen uns darauf, euch im Sommersemester 2026 wieder an der #FSGS begrüßen zu dürfen.

#fsgs #literatur #semesterferien #fuberlin

Proud today to share our latest work showing in vivo evidence that podocyte-derived ET-1 activating GEC ETA drives glomerular injury in FSGS. Congrats Liping Yu & @ubonge.bsky.social and big thanks to all co-authors for this tremendous team effort. #FSGS #nephrology #daehnlab @kidneyint.bsky.social

Podocyte derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis

doi.org/10.1016/j.kint.2026.01.014

#NephSky #MedSky #OpenAccess #FSGS

Editorial: Special Report
ICD-10 codes for APOL1-mediated kidney disease

doi.org/10.1016/j.kint.2025.09.025

#NephSky #MedSky #chronickidneydisease #FSGS #APOL1 @wakeforestmed.bsky.social

Im morgigen Mittagsforum der #FSGS stellt Luca Lil Wirth ihre Tätigkeit an der Alice Salomon Hochschule als Koordinatorin eines Drittmittelprojekts vor.

🔗 Zum Programm: bit.ly/fsgsmittagsg...

#Mittagsforum #Wintersemester202526 #fuberlin

Kidney News in Brief: FDA Delay for Sparsentan in FSGS, Decline in Deceased Donors and Transplants | Docwire News Kidney news includes an FDA delay for sparsentan in FSGS, falling deceased donor and kidney transplant numbers, a new chronic kidney disease (CKD) guideline, new board members NKF.

🗞️ CATCH UP with kidney news, including an FDA delay for sparsentan in #FSGS, a new #CKD guideline from two government agencies, and more. #nephsky #nephrology #kidneytransplant #kidneydisease www.docwirenews.com/post/kidney-...

Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis Health system-based biobanks with genetic data provide a unique opportunity for nephrotic syndrome (NS) genomic discovery. This is predicated on finding cases in the electronic-health-record.

Great collaboration with the @kidneyomicsamps.bsky.social lab! Thank you Matt for bringing back #MEFV for me, the disease that ignited my interest for #humangenetics when I was still a student! And now a risk factor for #FSGS! When things come together..

www.kidney-international.org/article/S008...

Sparsentan Safe and Effective for Pediatric Patients With FSGS | Docwire News A subanalysis of DUPLEX study data showed sparsentan resulted in proteinuria reduction for pediatric patients with focal segmental glomerulosclerosis (FSGS).

Pediatric results from DUPLEX show sparsentan is well tolerated and achieves superior, sustained proteinuria reduction versus the maximum IRB dose in FSGS. #KidneyWk #nephsky #Nephrology #FSGS #Pediatrics www.docwirenews.com/post/sparsen...

Dimerix Successfully Completes Recruitment for Phase 3 ACTION3 Trial of DMX-200 Dimerix Limited has successfully completed recruitment for its Phase 3 trial of DMX-200 in patients with FSGS, marking a significant milestone in kidney disease treatment.

Dimerix Successfully Completes Recruitment for Phase 3 ACTION3 Trial of DMX-200 #Australia #Melbourne #FSGS #Dimerix #DMX-200

Great collaboration with Florian Buerger, Friedhelm Hildebrandt, Jim Fawcett, @kidneyomicsamps.bsky.social, Markus Rinschen and many others. Huge thanks to all of our students who contributed so much to this work.

#raredisease #nephrology #nephtwitter #medtwitter #kidney #fsgs

Commentary
Mineralocorticoid receptor blockade quiesces parietal epithelial cell activation
Mallipattu S.

doi.org/10.1016/j.kint.2025.08.016

Original article: doi.org/10.1016/j.kint.2025.07.037

#MedSky #NephSky #ckd #chronickidneydisease #fsgs
@stonybrookmedicine.bsky.social

Donate to Andrew Boccafola-Fritz's Support Fund, organized by Christine Perrotta Help The Boccafola-Fritz Family Through Another Medical Crisis It takes a… Christine Perrotta needs your support for Andrew Boccafola-Fritz's Support Fund

My nephew is sick and the family is going through it right now. I don’t have a lot of followers but I’m hoping a couple of you see this and share. It would be greatly appreciated! ❤️
#GoFundMe #FSGS

gofund.me/2de4a5146

Interesting read on the protective p.N264k (M1) #APOL1 variant and #kidneydisease and #FSGS.
More to come soon on M1…. Stay tuned :)

@bhallaresearch.bsky.social
@gbadegesinlab.bsky.social @kidneyomicsamps.bsky.social

Sandeep Mallipattu, MD - Treating FSGS: Something Old, Something New, Something Still in Motion YouTube video by University of Washington Division of Nephrology

It was an honor for us to host Dr. Sandeep Mallipattu in #Seattle for Nephrology Grand Rounds! Take a look at his fantastic talk, "Treating FSGS: Something Old, Something New, Something Still in Motion." #kidney #nephrology #FSGS @uwmedicine.bsky.social #nephsky #meded

youtu.be/Nu8VZHuVTdY

Hilar variant of focal segmental glomerulosclerosis, with segmental sclerosis at the vascular pole with hyalinosis and adhesion (Jones silver stain)

bit.ly/49P5wQP (FREE)

#FSGS #renalpath

#MassSpectrometry of Minimal Change Disease and Focal Segmental Glomerulosclerosis #MCD #FSGS

#VisualAbstract by Sophia Ambruso

www.kireports.org/article/S2468-0249(25)00...

Sparsentan and the 0.7 g/g Proteinuria Threshold in FSGS | Docwire News Drs. Joel Topf and Jai Radhakrishnan discuss an analysis of data from the DUPLEX trial of sparsentan in focal segmental glomerulosclerosis (FSGS) and trial end points for FSGS.

Joel Topf @kidneyboy.bsky.social spoke with Jai Radhakrishnan at #KidneyWk about his late-breaking research poster describing a new analysis of data from the DUPLEX trial of sparsentan in #FSGS. #nephsky #nephrology www.docwirenews.com/post/sparsen...

Thank you @asnpublications.bsky.social !!!
This is a true honor, and a sprinkle of good luck!

#FSGS #rFSGS #raredisease #APOL1 #CAKUT #NephSky #SkyNeph
@asnkidney.bsky.social
@isgd.bsky.social

Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) ca. 2025 from @juancarlosqvelez.bsky.social
#Nephpearls #FSGS #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41222995/

Cellular variant of focal segmental glomerulosclerosis, with endocapillary hypercellularity with foam cells and mononuclear cells (top; Jones silver stain)"

bit.ly/4nNJdy2 (FREE)

#renalpath #FSGS

Tip lesion with localized sclerotic lesion only involving the proximal tubular pole of the glomerulus (Jones silver stain).

FREE The tip lesion variant of focal segmental glomerulosclerosis (FSGS) is associated with nephrotic syndrome and usually responds to steroid therapy. This #FSGS variant has the lowest risk for progression to kidney failure.

bit.ly/47tgF8l #RenalPath

Renalys Pharma Finalizes Agreement with Japan's PMDA for Clinical Trials of Sparsentan Renalys Pharma announces a key agreement with Japan's PMDA for Phase III trials of Sparsentan aimed at treating FSGS and Alport Syndrome, with a focus on enhancing kidney health.

Renalys Pharma Finalizes Agreement with Japan's PMDA for Clinical Trials of Sparsentan #Japan #Tokyo #Sparsentan #Renalys_Pharma #FSGS

Highly recommended contribution from Detlef Bockenhauer et al: a modern view of the genetic landscape of kidney diseases!
#genetics #CAKUT #FSGS #APOL1 #NephSky #SkyNeph #Medsky #raredisease #RKD
@melaniechan.bsky.social @oalavijeh.bsky.social @horiastanescu.bsky.social @dannygale.bsky.social

Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis.

doi.org/10.1016/j.kint.2025.07.037

#OpenAccess #NephSky #MedSky #CKD #FSGS #chronickidneydisease @parcc-inserm.bsky.social @rwth.bsky.social

Exciting expansion!!
#FSGS #APOL1